Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Y90 Radioembolization as Neoadjuvant Therapy for Potentially Resectable Patients With Colorectal Liver Metastases: Immune Markers Evaluation, Impact on Circulating Tumor DNA and Personalized Dosimetry Approach

NCT07406126 is registered in ClinicalTrials.gov with Fernando Gómez Muñoz as lead sponsor.

NCT NCT07406126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07406126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Y90 Radioembolization as Neoadjuvant Therapy for Potentially Resectable Patients With Colorectal Liver Metastases: Immune Markers Evaluation, Impact on Circulating Tumor DNA and Personalized Dosimetry Approach
Lead sponsor
Fernando Gómez Muñoz
Phase
Observational
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
July 31, 2028
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal liver metastases (crclm), unresectable colorectal liver metastases